PHASE II CLINICAL TRAILS OF NNZ-2566

$27,492,373FY2009Department of DefenseDOD

Neuren Pharmaceuticals, Inc.

Investigators

View source on USAspending →

PHASE II CLINICAL TRAILS OF NNZ-2566 · GrantIndex